Beacon enters drug discovery collaboration with Janssen
Pharmaceutical Technology | January 08, 2018
US-based drug discovery firm Beacon Discovery has entered a multi-year collaboration agreement with Janssen Pharmaceuticals for small molecule compounds to treat metabolic diseases. The partnership is set to discover and develop compounds for various undisclosed G-protein coupled receptor (GPCR) targets. It will also involve research for identifying drug candidates to treat diseases, such as obesity, with significant unmet medical need. Under the agreement, Janssen exercises an option to acquire worldwide rights for the development, manufacture and commercialization of products resulting from the alliance. The firm will, in turn, pay an upfront amount to Beacon, along with milestones and royalties on future sales of products that would be related to exercise of the option.